Enrolling BMT CTN Studies

Bone marrow transplant for untreated severe aplastic anemia (BMT CTN 2207; CureAA)

• Study Goal: to find out if bone marrow transplant works as the first treatment for people diagnosed with severe aplastic anemia
• Patient Summary: coming soon
• Patient Consent Form: coming soon
• Status: The study will be open to patients in the summer of 2024. More information will be available soon.

For additional clinical trials for aplastic anemia, Visit Here.

Three drugs, treosulfan, fludarabine and lapine T-lymphocyte immune globulin (rATG), before allogeneic (cells from a donor) blood or marrow transplant to treat bone marrow failure disorders in children, teens and adults (BMT CTN 1904)

• This study is for people with bone marrow failure disorders such as: 
  • Congenital amegakaryocytic thrombocytopenia (CAMT)
  • Congenital sideroblastic anemia (CSA)
  • Diamond Blackfan anemia (DFA)
  • GATA2 deficiency
  • Paroxysmal nocturnal hemoglobinuria (PNH)
  • SAMD9 disorder
  • SAMD9L disorder
  • Shwachman-Diamond syndrome (SDS)
  • Other bone marrow failure disorder, even if the cause is unknown
• Study goal: to find out if the adding the drug treosulfan to treatment before transplant will cause fewer complications and make transplant work better
• Patient Consent Form
• Status: The study is open to new patients
• Eligibility and site location information
• For More Info: Protocol (detailed study information)

For additional bone marrow failure clinical trials, Visit Here.
 

• BMT CTN doesn’t have any current clinical trials for this diagnosis. To find open clinical trials for leukemia or MDS, visit the NMDP Clinical Trials Search and Support website

• Autologous (cells from the patient) blood or marrow transplant followed by HST-NEETs for treatment of HIV-associated lymphoma (BMT CTN 1903)
  • Study goal: to see if a type of cells called HST-NEETs can help fight HIV. HST-NEETs are cells made from the patient’s own immune cells that have been treated and grown in a lab.
  • Patient Consent Form
  • Status: The study is open to new patients
  • Eligibility and site location information
  • For More Info: Protocol (detailed study information)
• For additional clinical trials, visit the NMDP Clinical Trials Search and Support website:
  • HIV studies
  • Lymphoma studies

• Chimeric Antigen Receptor T Cell (CAR T-cell) therapy for patients with multiple myeloma after autologous (cells from the patient) blood or marrow transplant (BMT CTN 1902)
  • Study goal: to see if CAR T-cell therapy can treat multiple myeloma when standard treatment didn’t work. CAR T-cell therapy uses a patient’s own cells that have been treated in a lab so they can attack cancer cells.
  • Patient Consent Form
  • Status:
    • This study is closed to new patients.
    • Study results will be available by February 2025. A summary will be posted on this website.
  • Eligibility and site location information
  • For More Info: Protocol (detailed study information)
  • For additional information about multiple myeloma studies, Visit Here.

• Gene therapy for patients with sickle cell disease (BMT CTN 2001; GRASP)
  • Study goal: to find out if gene therapy is safe, and if it reduces symptoms of sickle cell disease. 
  • Patient Consent Form
  • Status: The study is open to new patients
  • Eligibility and site location information
  • For More Info: Protocol (detailed study information)

For additional information about sickle cell disease studies, Visit Here.

BMT CTN doesn’t have any current clinical trials for other diagnoses. To find open clinical trials, visit the NMDP Clinical Trials Search and Support website